What Telehealth's Pandemic Scaling Taught Us About What Patients Actually Need

Before 2020, telehealth adoption in the United States was moving at the pace of a policy seminar. Reimbursement rules were narrow, geographic restrictions locked out most urban patients, and many health systems treated video visits as a novelty for dermatology and minor urgent care. Then the restrictions lifted almost overnight, and the entire architecture of American outpatient medicine ran an unplanned experiment on roughly 330 million people.

What scaled quickly was not surprising in retrospect. Behavioral health was the clearest winner. Therapy and psychiatry visits translated to video with relatively low friction because the clinical interaction is primarily verbal, no stethoscope required. Patients who had previously skipped care because of transportation, stigma, or schedule conflicts found a format that worked. Wait times for some outpatient mental health slots shortened because providers could see more patients per day without room-turnover constraints. That pattern has largely held.

Primary care for established patients with stable, well-documented conditions also performed reasonably well. A clinician who already knows a patient's chart, baseline vitals, and medication history can manage a blood pressure follow-up or a medication refill by video without much lost in translation. The visit is thinner than an in-person encounter, but for that specific task it is often sufficient.

What did not scale cleanly is worth naming precisely, because the press coverage of telehealth has sometimes glossed over it. New patient evaluations are harder. A clinician meeting someone for the first time over video cannot do a physical exam, cannot observe gait or skin color under good light, cannot catch the finding that was not in the chief complaint. Emergency department diversion programs that routed undifferentiated patients to telehealth first learned this the hard way in some settings, with missed diagnoses that required after-the-fact review.

Pediatrics carried its own complications. Parents became de facto examiners, asked to describe what they were seeing in a febrile two-year-old. Some did that well. Others could not, and the clinician on the other end was working with incomplete information and knew it.

The equity story is genuinely mixed. Telehealth removed barriers for patients with reliable broadband, a quiet space, and a device with a camera. It added barriers for patients without those things. Older adults on fixed incomes, rural households with poor connectivity, and patients in multi-generational housing without privacy all faced friction that in-person care did not create. Audio-only visits filled some of that gap, and reimbursement for phone visits became a real policy fight because of it.

What appears to have settled, at least structurally, is a hybrid model that most large health systems are now running by default. Follow-up visits for chronic disease management, behavioral health, and established-patient acute concerns stay virtual at relatively high rates. First-time consultations, procedural visits, and anything requiring physical examination pull patients back in. Some specialty practices, particularly in dermatology and ophthalmology, built asynchronous workflows where patients submit photos or data ahead of time and the clinician reviews on their own schedule.

The regulatory question that will shape all of this going forward is reimbursement parity. When payers reimburse a video visit at a lower rate than an in-person visit for the same code, health systems have a financial incentive to bring patients back to the building regardless of clinical need. Clinicians who built telehealth practices during the emergency period are watching rate schedules closely.

For patients, the practical takeaway is straightforward. If your visit requires a physical exam, go in. If it is a follow-up on something already established and documented, ask whether video works. The question is clinical fit, not technology enthusiasm.